October 2018

October 2018

Welcome to the October issue. Upfront investigates next-generation pain medications developed with computer simulations, antibiotics derived from bear saliva, and the costs of falsified medicine. Daniel Maier argues that the development of an industrial process should begin when the product is still at the preclinical stage in “In My View”, while our cover feature examines the urgent need for pharma to generate data on safety for pregnant and lactating women and their fetuses and babies. In Best Practice, Mike Merges and Mike Sadick from Catalent discuss how to get analytical bioassay cell banks up and running, and in Business, we explore a proactive approach to discovering and investing in future leaders. We also Sit Down With…Kal Patel, MD, Senior Vice President of Digital Health for Flex.

Recent Issues